Research Collaboration Overview Clause Samples
The Research Collaboration Overview clause defines the general framework and objectives for a joint research effort between parties. It typically outlines the scope of the collaboration, the roles and responsibilities of each party, and the intended outcomes or deliverables of the project. For example, it may specify the research areas to be explored, the duration of the collaboration, and the mechanisms for coordinating activities. This clause serves to establish a clear mutual understanding of the collaboration's purpose and structure, helping to align expectations and prevent misunderstandings at the outset of the partnership.
Research Collaboration Overview. The Parties have agreed to engage in the Research Collaboration in accordance with the terms set forth in this Agreement. The Research Collaboration is aimed at the discovery and optimization of chemical entities that bind the Collaboration Targets and will be conjugated to certain chelator agents to result in Selected Conjugates that satisfy the target product profile set forth in the Research Plan. The Parties will use Commercially Reasonable Efforts to perform their respective obligations under the Research Collaboration as further specified in this Agreement and in the Research Plan. The Research Plan will describe [***]. No activities under the Research Collaboration shall take place except as described in the Research Plan, and except as otherwise agreed by the Parties in writing, each Party shall be solely responsible for all costs it incurs to conduct its Collaboration Activities.
Research Collaboration Overview. The Researching Parties shall conduct a research collaboration program under which they will work together during the Research Term in accordance with a Research Plan to (a) discover and validate epigenetic targets in the following target Classes: [**] (but excluding BET and EZH2) (“Targets”), and (b) discover and develop compounds suitable for clinical development and commercialization that bind to and modulate such Targets (the “Research Collaboration”). In addition, the JRC may agree in writing to include other epigenetic targets within the Research Collaboration, and following final agreement on such targets by the JRC they shall thereafter be deemed Targets under the terms of this Agreement.
Research Collaboration Overview. 1.1.1. The intent of the Research Collaboration is for the Parties to conduct (1) a core technology research program focused on growing the Parties’ collective knowledge on systemic delivery of ASO interactions in tissues and cell types relevant to Primary Diseases, (2) a disease research program focused on the identification, validation, and applications of certain novel Targets to treat the Primary Diseases, and (3) a drug discovery program focused on Targets that meet certain Target Sanction success criteria in the disease research program.
1.1.2. At the beginning and throughout the term of the disease research program, the Parties (including through the JSC) will collaboratively discuss and identify Targets that the Parties are potentially interested in pursuing in the disease research program to treat the Primary Diseases. When Targets of interest are identified, the JSC will determine which Targets are eligible for inclusion in the disease research program. AstraZeneca may either add such Eligible Targets directly to the High Interest Target List to commence the work necessary to validate such Targets, or hold a limited number of such Eligible Targets in reserve for a period of time (before deciding whether to add such Targets to the High Interest Target List).
1.1.3. Isis, and in some cases together with AstraZeneca, will perform Target validation activities under the disease research program on Eligible Targets that the JSC (or AstraZeneca) has added to the list of High Interest Targets. Once a High Interest Target reaches Target Sanction, the JSC may select such Target to be the subject of a Collaboration Program under this Agreement.
1.1.4. For each Collaboration Program, Isis will use Commercially Reasonable Efforts to conduct drug discovery activities and generate [***] Lead Candidate for the JSC to consider designating as a Development Candidate.
Research Collaboration Overview